The mTOR pathway in lung cancer and implications for therapy and biomarker analysis - PubMed (original) (raw)
Review
The mTOR pathway in lung cancer and implications for therapy and biomarker analysis
Simon Ekman et al. J Thorac Oncol. 2012 Jun.
Free article
Abstract
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulatory protein in normal cell growth, survival, metabolism, development, and angiogenic pathways. Deregulation of these processes is a required hallmark of cancer, and dysregulation of mTOR signaling frequently occurs in a wide variety of malignancies, including lung cancer. Targeting of mTOR is thus an attractive strategy in the development of therapeutic agents against lung cancer. In this review, the mTOR-signaling pathway is described, highlighting opportunities for therapeutic intervention and biomarker analysis, and clinical trials in lung cancer including both non-small cell lung cancer and small cell lung cancer.
Similar articles
- [Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer].
Lin Y, Zhang L. Lin Y, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Apr;32(2):239-42. doi: 10.3881/j.issn.1000-503X.2010.02.025. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010. PMID: 20450558 Review. Chinese. - LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D, Li SJ, Zhu YT, Liu L, Li MX. Han D, et al. Asian Pac J Cancer Prev. 2013;14(7):4033-9. doi: 10.7314/apjcp.2013.14.7.4033. Asian Pac J Cancer Prev. 2013. PMID: 23991948 Review. - Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT, Ismail A, Tolomeo C. Beck JT, et al. Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3. Cancer Treat Rev. 2014. PMID: 25037117 Review. - mTOR in Lung Neoplasms.
Krencz I, Sebestyen A, Khoor A. Krencz I, et al. Pathol Oncol Res. 2020 Jan;26(1):35-48. doi: 10.1007/s12253-020-00796-1. Epub 2020 Feb 3. Pathol Oncol Res. 2020. PMID: 32016810 Review. - Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Fumarola C, et al. Biochem Pharmacol. 2014 Aug 1;90(3):197-207. doi: 10.1016/j.bcp.2014.05.011. Epub 2014 May 24. Biochem Pharmacol. 2014. PMID: 24863259 Review.
Cited by
- mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies.
Sztankovics D, Moldvai D, Petővári G, Dankó T, Szalai F, Miyaura R, Varga V, Nagy N, Papp G, Pápay J, Krencz I, Sebestyén A. Sztankovics D, et al. Pathol Oncol Res. 2024 Mar 7;30:1611643. doi: 10.3389/pore.2024.1611643. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38515456 Free PMC article. Review. - Recent advances in non-small cell lung cancer targeted therapy; an update review.
Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Araghi M, et al. Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review. - MRPL51 is a downstream target of FOXM1 in promoting the malignant behaviors of lung adenocarcinoma.
Zhang W, Yu L, Xu C, Tang T, Cao J, Chen L, Pang X, Ren W. Zhang W, et al. Oncol Lett. 2023 May 26;26(1):298. doi: 10.3892/ol.2023.13884. eCollection 2023 Jul. Oncol Lett. 2023. PMID: 37323822 Free PMC article. - PKNOX2 suppresses lung cancer cell proliferation by inhibiting the PI3K/AKT/mTOR axis.
Song M, Zhang N, Cao F, Liu J. Song M, et al. Exp Ther Med. 2023 Mar 28;25(5):217. doi: 10.3892/etm.2023.11917. eCollection 2023 May. Exp Ther Med. 2023. PMID: 37123214 Free PMC article. - Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer.
Lee SH, Kim EY, Han JM, Han G, Chang YS. Lee SH, et al. Cancer Res Treat. 2023 Jul;55(3):851-864. doi: 10.4143/crt.2022.1527. Epub 2023 Mar 20. Cancer Res Treat. 2023. PMID: 36960627 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous